Study: "Atogibant" can help treat the most difficult migraines

An American initial study, recently published, found that a protective characteristic of migraine called ‘Atogibant’ could help treat the most difficult cases. The new study, presented at the 75th annual meeting of the American Academy or Neurological Medicine, was especially considered as data related to people with transverse migraines, who do not respond to other medicines. The study included about 300 people suffering from accidental migraines, who tried at least two different categories of preventative migraines, and about half of it received 60 mg of “atogibant” daily (the highest recognized dose), while the other half received a false treatment. The study showed that patients with migraines and who did not respond to other treatments had significantly headache attacks during the use of the new medicine, compared to those treated with an imaginary drug. Both groups were a decrease in migraine days, but those who took “Atogibant” suffered on average less than two days to a migraine compared to the imaginary medicine. The study also showed that the drug was safe and good tolerance, and the most common side effects were constipation and nausea, which affected up to 10% of patients. ‘Exciting results’, author of study Patricia Bozo Rosich, a researcher at Val Dipron University Hospital in Barcelona, ​​said in a statement issued by the American Academy of Neuroscience the results are ‘exciting’. She added: “Migraine can be exhausted, and this treatment has reduced migraines for people who have already tried up to 4 other types of medication to prevent migraines and do not have side effects, or have side effects that exceed any benefits.” The ‘atogibant’ is a drug that belongs to a group of medicines known as ‘peptide’, associated with calcitonin (CGRP) as it works by preventing the activity of the molecule participating in the migraine process. Unlike the peptide associated with other calcitonin gene, this medicine is taken orally and not by injection, while still undergoing clinical trials, but the initial results have shown that it is effective in reducing the rate and intensity of migraine in adults. The US Food and Drug Administration has expanded the intended use of the drug this month as it has been approved for adults with chronic migraines. The new results have not yet been published in a magazine reviewed by the peers, which is an important part of the scientific process, but it is new to the wake of other good news associated with the medicine. Last week, the US food administration agreed to expand the use of ‘atogibant’ based on positive experimental data data, and it has now been approved to prevent casual and chronic migraines, which are defined for 15 days or more per month. Also read: